Week of August 19, 2024: 5 “Strong Buy” Stocks Under $30

Looking for low-priced stocks with a big thumbs up from top-rated analysts? Look no further. We sourced the below list from WallStreetZen's Top Analysts (a premium feature on our site) which showcases stock ratings from the best stock analysts in the world. 

1- Americold Realty Trust (NASDAQ: COLD) 

Analyst/Firm: Ki Bin Kim / Truist Securities

Analyst ranking: Top 11% / average return +7.98% / win rate 59% 

Yesterday’s market close: $28.86 (8/19 — see latest price here)

Price target: $33.00 

• Maintaining a Strong Buy rating, Truist Securities's Ki Bin Kim raised their price target on Americold Realty Trust (NYSE: COLD) by 6.5% from $31 to $33 on 8/16.
• Kim reported that their price target hike was catalyzed by a deep dive into their Financial (REITs) sector coverage area.
• Factors the analyst cited for their model adjustments included the company’s Q2 2024's results and adjusted revenue growth and expense assumptions.
• See additional forecasts and ratings for COLD here.

1-year chart for COLD, courtesy TradingView 

2- Cellebrite Di Ltd. (NASDAQ: CLBT) 

Analyst/Firm: Tal Liani / Bank of America

Analyst ranking: Top 10% / average return +12.57% / win rate 59% 

Yesterday’s market close: $16.37 (8/19 — see latest price here)

Price target: $17.00 

• Maintaining a Strong Buy rating, Bank of America's Tal Liani raised their price target on Cellebrite Di (NASDAQ: CLBT) by 30.8% from $13 to $17 on 8/16. Here’s why: 
• Cellebrite Di delivered a quarterly beat, Liani summed up after assessing the company's 8/15-dated Q2 2024 earnings report.
• The analyst detailed that the company reported Y/Y revenue growth of 24.8% and beat the consensus EPS estimate by $0.03.
• Further, Liani noted that management's Q3 and Q4 guidance was higher than the Street consensus across all metrics, showing a solid demand environment.
• Will CLBT see 20% upside or more in the coming year? See what analysts are saying.

1-year chart for CLBT, courtesy TradingView 

3- Gambling.com Group (NASDAQ: GAMB)

Analyst/Firm: Barry Jonas / Truist Securities

Analyst ranking: Top 14% / average return +7.63% / win rate 45%  

Yesterday’s market close: $10.17 (8/19 — see latest price here)

Price target: $13.00 

• ​​Truist Securities's Barry Jonas reiterated their Strong Buy rating and raised their price target on Gambling.com Group (NASDAQ: GAMB) by 8.3% from $12 to $13 on 8/16.
• Rising NDCs (New Depositing Customers) and resilient North American business helped propel the company's adjusted EBITDA to a significant beat, Jonas highlighted after reviewing Gamblingcom Group's 8/15-dated Q2 2024 print.
• Citing Management raised its FY 2024 guidance because the impact of Google's search ranking methodology change was less significant than expected, the analyst noted.
• Wow! The max 1-year forecast for GAMB suggests 37% upside potential. See more.

1-year chart for GAMB, courtesy TradingView 

4- National Cinemedia Inc. (NASDAQ: NCMI) 

Analyst/Firm: Eric Wold / B. Riley Securities

Analyst ranking: Top 4% / average return +13.95% / win rate 53% 

Yesterday’s market close: $6.75 (8/19 — see latest price here)  

Price target: $8.50 

• Maintaining a Strong Buy rating, B. Riley Securities's Eric Wold raised their price target on National Cinemedia (NASDAQ: NCMI) by 13.3% from $7.5 to $8.5 on 8/16. 
• Wold reported that their price target move was catalyzed by a meeting with management, from which they came away " increasingly confident in National Cinemedia's multiple revenue growth drivers over the next few years" and the "attractive operating leverage and cash flow conversion that should accompany that revenue growth."
• See more forecasts for NCMI here.

1-year chart for NCMI, courtesy TradingView 

5- Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) 

Analyst/Firm: Yigal Nochomovitz / Citigroup

Analyst ranking: Top 7% / average return +9.46% / win rate 46% 

Yesterday’s market close: $20.50 (8/19 — see latest price here)

Price target: $34.00 

• Maintaining a Strong Buy rating, Citigroup's Yigal Nochomovitz raised their price target on Syndax Pharmaceuticals (NASDAQ: SNDX) by 13.3% from $30 to $34 on 8/16. 
• Nochomovitz's price target hike was catalyzed by the FDA's approval of Niktimvo, which was announced on 8/15. Niktimvo is a prescription medication for the treatment of cGVHD (Chronic Graft-Versus-Host Disease) after the failure of at least two prior treatments.
• With this green light, Syndax should "officially" become a commercial enterprise, the analyst told investors.
• Read about SNDX’s 119% upside potential in the next year — click here.

1-year chart for SNDX, courtesy TradingView 

Gain access to dozens of alerts like this per week — Click the button below.

👉👉 Try WallStreetZen Premium for just $1

Want to get in touch? Email us at news@wallstreetzen.com.